y 27632 has been researched along with 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide in 3 studies
| Studies (y 27632) | Trials (y 27632) | Recent Studies (post-2010) (y 27632) | Studies (2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide) | Trials (2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide) | Recent Studies (post-2010) (2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide) |
|---|---|---|---|---|---|
| 1,924 | 3 | 891 | 63 | 0 | 51 |
| Protein | Taxonomy | y 27632 (IC50) | 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide (IC50) |
|---|---|---|---|
| Inhibitor of nuclear factor kappa-B kinase subunit beta | Homo sapiens (human) | 0.0189 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.02 | |
| Interferon-induced, double-stranded RNA-activated protein kinase | Homo sapiens (human) | 0.25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cox, KJ; Gaj, A; Ghosh, I; Jester, BW; Shomin, CD | 1 |
| Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
| Boakes, A; Crighton, D; Heikkila, T; Kaye, SJ; Mezna, M; Olson, MF; Pang, L; Rushbrooke, M; Schroder, E; Turnbull, A; Wheatley, E | 1 |
3 other study(ies) available for y 27632 and 2-((aminocarbonyl)amino)-5-(4-fluorophenyl)-3-thiophenecarboxamide
| Article | Year |
|---|---|
Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen.
Topics: Animals; Binding, Competitive; Catalytic Domain; Cell-Free System; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Cyclic GMP-Dependent Protein Kinase Type I; Cyclic GMP-Dependent Protein Kinases; Databases, Factual; Genes, Reporter; Luciferases; Protein Kinase C; Protein Kinase Inhibitors; Rabbits; Recombinant Fusion Proteins; Structure-Activity Relationship | 2012 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |
Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Catalytic Domain; Cell Line, Tumor; Collagen; Crystallography, X-Ray; Drug Combinations; Extracellular Matrix; Humans; Inhibitory Concentration 50; Laminin; Models, Molecular; Myotonin-Protein Kinase; Neoplasm Invasiveness; Protein Kinase Inhibitors; Protein Multimerization; Protein-Tyrosine Kinases; Proteoglycans; Pyridines; rho-Associated Kinases; Thiophenes | 2011 |